TME Pharma reports H1 2022 Financial results and provides business update
Promising top-line results warrant focus of the clinical development on NOX-A12 combination therapies in brain cancer NOX-A12 + bevacizumab 12-month survival data in glioblastoma expected in April 2023 Cash runway into June 2023 TME Pharma N.V. (Euronext Growth Paris: ALTME), Mehr